Saturday 17 October 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024. In the quarter to June 2026, revenue grew 55.4%, EPS grew 37.5% and free cash flow grew 66.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for five.

78.59 1.35 −1.69%

Follow KNSA

Alert me

Market cap: $6.2B
P/E: 73.4×
Fwd P/E: 38.7×
Dividend yield: —
F-score: 8/9
Altman Z: 10.35
Beneish M: −3.16
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
P/E ratio Full definition →	+8 more quarters Free account	79.24	51.56	49.13	59.77
P/S ratio Full definition →		4.85	4.52	4.89	5.90
P/FCF ratio Full definition →		28.49	22.42	22.42	27.12
P/Operating CF Full definition →		86.15	56.79	73.39	105.12
P/B ratio Full definition →		5.42	5.39	6.08	7.58
Price to Tangible BV Full definition →		5.58	5.54	6.24	7.76
EV/Sales Full definition →		4.26	3.91	4.27	5.27
EV/EBITDA Full definition →		64.30	33.60	33.89	43.46
EV/Operating CF Full definition →		24.78	19.18	19.39	23.98
EV/FCF Full definition →		25.03	19.39	19.57	24.25
Quick Ratio Full definition →		3.27	3.09	3.14	3.21
Current Ratio Full definition →		3.85	3.79	3.79	3.90
Net Debt/EBITDA Full definition →		(14.43)	(20.46)	(15.74)	(19.01)
Debt/Assets Full definition →		0.00%	0.00%	0.00%	0.00%
Debt/Equity Full definition →		0.00	0.00	0.00	0.00
Asset Turnover Full definition →		0.94	1.01	1.06	1.08
Operating CF/Net income Full definition →		1.83	3.80	2.22	1.86
Capex/Depreciation Full definition →		(1.75)	(1.36)	(0.34)	(1.40)
Research and Development Expense of Revenue Full definition →		13.36%	17.12%	12.82%	16.79%
Selling, General and Administrative Expense of Revenue Full definition →		27.15%	28.09%	28.54%	26.22%
Intangible Assets out of Total Assets Full definition →		0.02	0.02	0.02	0.02
Share Based Compensation of Revenue Full definition →		5.61%	5.06%	4.69%	4.78%
Graham Net Nets Full definition →		0.10	0.11	0.10	0.09
Graham Number Full definition →		8.89	11.73	13.21	14.25
Earnings Yield Full definition →		1.26%	1.94%	2.04%	1.67%
Free Cash Flow Yield Full definition →		3.51%	4.46%	4.46%	3.69%
Revenue per Share Full definition →		2.42	2.72	2.80	3.14
Operating CF per Share Full definition →		0.45	0.73	0.66	0.61
Capex per Share Full definition →		(0.01)	(0.01)	0.00	(0.01)
Free Cash Flow per Share Full definition →		0.44	0.72	0.65	0.60
Cash per Share Full definition →		4.71	5.58	6.12	6.78
Shareholders Equity per Share Full definition →		7.17	7.65	7.92	8.43
Interest Debt per Share Full definition →		0.00	0.00	0.00	0.00
Book value per Share Full definition →		7.17	7.65	7.92	8.43
Free Cash Flow Full definition →		33.01	53.26	50.04	46.53
Working Capital Full definition →		351.94	387.99	437.56	497.39
Capital Expenditures Full definition →		(0.67)	(0.63)	(0.16)	(0.66)
Net Current Asset Value Full definition →		298.58	331.15	374.58	426.67
EV/EBIT Full definition →		66.81	34.27	34.50	44.24
Capex to Sales Full definition →		0.00	0.00	0.00	0.00
Price to Operating Income Full definition →		76.04	39.64	39.52	49.49
Other line items
Average Receivables Full definition →		38.32	28.66	31.64	27.70
Average Payables Full definition →		7.24	2.03	13.19	10.68
Average Inventory Full definition →		35.04	40.63	47.61	59.56
Average Assets Full definition →		633.82	672.09	712.30	778.63
Average Common Equity Full definition →		486.19	503.02	531.59	574.58

Show all line items

Columns are period end dates

Stockrow Weekly